



BTOG Webinar: ASCO in an Hour 2022

Thursday 23rd June 2022

17:30 to 18:30

Approved for 1 category 1 (external) CPD credit (reference 140730)

From the Federation of the Royal Colleges of Physicians of the United Kingdom

To join this event, please register at www.btogwebinars.org

If you have previously registered at www.btogwebinars.org (for a previous BTOG webinar), you do not need to re-register, just log in on or before Thursday 16th June 2022 and you will be able to join the live event.

Chair: Dr Tom Newsom-Davis – BTOG Steering Committee Vice-Chair

17:30 Immunotherapy in Thoracic Cancers

Alastair Greystoke

17:45 Mutation Driven NSCLC

Riyaz Shah

18:00 Adjuvant, Neo-Adjuvant and Locally Advanced Data

Gerry Hanna

18:15 Panel discussion led by Chair

18:30 Close

Sponsors

**Sponsors have not been involved or influenced
the content and the agenda of the meeting.**



Biographies

Dr Alastair Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle and has a special interest in the development of new anti-cancer drugs for patients with thoracic malignancies. In addition, he is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in NSCLC), Clinical Lead for Cancer for the Yorkshire, Hull and Northeast England Genomic Laboratory Hub and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.

Professor Gerard G Hanna MB BCH PhD MRCP(UK) FRCR FRANZCR is Clinical Director of the Northern Ireland Cancer Centre, past Director of Radiation Oncology at the Peter MacCallum Cancer Centre, Melbourne and holds honorary appointments with Queen's University Belfast and the University of Melbourne. Research interests include the use of PET/CT in radiotherapy planning for lung cancer, mechanisms of radiotherapy resistance, stereotactic ablative radiotherapy and systemic therapy and immunotherapy combinations with radiotherapy.

Dr Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been a member of the BTOG Steering Committee for the past 2 years, and until recently was part of the National Cancer Research Institute Lung Group and led the RM Partners Cancer Vanguard lung pathway. Dr Newsom-Davis is actively involved in clinical research and has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including BTOG, the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.

Dr Riyaz Shah qualified from Guy's and St Thomas Hospitals in 1994 and obtained Membership of the Royal College of Physicians of London in 1997. He completed junior medical training in London and was subsequently awarded an Imperial Cancer Research Fund Clinical Research Fellowship that led to the completion of a PhD from Imperial College/ Hammersmith Hospital (1998-2001). His research focused on gene transcriptional irregularities in cancer and gene therapy. Dr Shah completed Medical Oncology training at The Royal Marsden Hospital (2002-2006) before being appointed as a Consultant Medical Oncologist at the Kent Oncology Centre (2006-). He was awarded an ASCO Foundation Merit Award in 2005 for his work in a cancer known as carcinosarcoma. Dr Shah specialises in thoracic and gastrointestinal malignancies and provides NHS clinics at Darent Valley, Maidstone and Tunbridge Wells Hospitals. He is active in several local and national committees. At the time of writing he is the Chairman of the Lung Tumour Site Specific Group for the Kent Cancer Collaborative, Lead for Research at KOC, Member of the NCRI Lung Clinical Studies Group and Member of the Thoracic Surgery Clinical Reference Group. He has a major interest in clinical research and acts as principal investigator on many trials in Kent. He was the UK Chief Investigator of the Lux LUNG 5 trial. He has published widely and is regularly invited to speak at local, national and international meetings.